What Labcorp's FY2025 10-K says: 12 signals
Labcorp filed its latest 10-K with the SEC on Feb 24, 2026. It discusses acquisition completed, AI investment and capex increase.
Public (LH)Hospitals and Health Care10,000+ employeeslabcorp.comLinkedIn
- Filed
- Feb 24, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What Labcorp's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Company invested $582M in strategic acquisitions in 2025, including a stake in Europe's SYNLAB.
Labcorp is actively using acquisitions to enhance service offerings and expand its geographic footprint.
$582M
Investment in strategic business acquisitions during 2025
Labcorp launched a generative AI tool, "Test Finder," for clinical test selection
The company has implemented a generative AI tool to help healthcare providers use plain-language prompts to find relevant tests.
Generative AI
Plans to increase capital expenditures to ~4.0% of revenue from $434.5M in 2025
The company is increasing its capital spending to support business growth, facility expansions, acquisition integrations, and its 'LaunchPad' program.
$434.5M
Capital expenditures during 2025
4%
Expected capital expenditures as a percentage of revenue
Facing renewed margin pressure as PAMA reimbursement cuts of up to 15% annually resume in 2027.
After a temporary freeze, Medicare reimbursement rate decreases under PAMA will resume in 2027 and continue through 2029, capped at 15% per year.
15%
Annual cap on PAMA-based rate decreases from 2027-2029
Managed Care Organizations (MCOs) are implementing stricter measures to control laboratory testing volume and expense, directly impacting Labcorp's revenue.
Labcorp is expanding its cell and gene therapy lab in Madison, Wisconsin to increase capacity.
This facility expansion into a high-growth, technologically advanced field necessitates investment in specialized lab equipment, advanced data analytics platforms, and secure IT infrastructure to handle sensitive R&D and clinical trial data.
Cell and Gene Therapy
Labcorp completed 13 collaboration transactions with health systems and local labs in 2025.
This high volume of partnerships creates a recurring need for IT integration services, data sharing platforms, and workflow automation tools to connect Labcorp's systems with those of its new partners, ensuring seamless operations and data exchange.
Labcorp is investing in digital pathology platforms to enable remote collaboration and data sharing.
Digital Pathologydata and analytics
Spent $582M on strategic acquisitions in 2025, driving need for integration services
Labcorp invested $582 million in acquisitions in 2025 and has budgeted further capital for integration activities.
$582M
Investment in strategic business acquisitions during 2025
Implementing digital pathology solutions to digitize and centralize slide review
The company is rolling out technology platforms to digitize pathology slides, enabling remote collaboration and scalable data access.
cloud
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Labcorp with the Signal API
One POST /v1/companies/enrich call with labcorp.com returns Labcorp 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"labcorp.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Labcorp 10-K
When did Labcorp file its latest 10-K?
What does Labcorp's latest 10-K say about capex increase?
Where can I find Labcorp's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .